NASDAQ:OMCL - Omnicell Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $129.25
  • Forecasted Upside: -12.05 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$146.96
▲ +3.28 (2.28%)

This chart shows the closing price for OMCL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Omnicell Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OMCL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OMCL

Analyst Price Target is $129.25
▼ -12.05% Downside Potential
This price target is based on 9 analysts offering 12 month price targets for Omnicell in the last 3 months. The average price target is $129.25, with a high forecast of $165.00 and a low forecast of $84.00. The average price target represents a -12.05% upside from the last price of $146.96.

This chart shows the closing price for OMCL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 polled investment analysts is to buy stock in Omnicell. This rating has held steady since January 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/9/2021JPMorgan Chase & Co.Initiated CoverageNeutral$146.00Low
5/24/2021BTIG ResearchInitiated CoverageBuy$165.00Low
4/30/2021BenchmarkBoost Price TargetBuy$155.00 ➝ $160.00Low
4/30/2021Piper SandlerBoost Price TargetOverweight$147.00 ➝ $152.00Medium
3/22/2021BenchmarkBoost Price TargetBuy$140.00 ➝ $155.00Low
2/2/2021Piper SandlerUpgradeNeutral ➝ Overweight$86.00 ➝ $147.00N/A
1/20/2021BenchmarkBoost Price TargetBuy$125.00 ➝ $140.00Low
1/14/2021Craig HallumBoost Price TargetBuy$100.00 ➝ $142.00Low
12/9/2020BenchmarkBoost Price TargetBuy$100.00 ➝ $125.00High
12/8/2020Berenberg BankInitiated CoverageBuyHigh
12/3/2020Cantor FitzgeraldDowngradeOverweight ➝ Neutral$95.00High
10/28/2020Craig HallumBoost Price TargetBuy$85.00 ➝ $100.00High
10/28/2020Wells Fargo & CompanyBoost Price TargetEqual Weight$74.00 ➝ $84.00Low
10/28/2020BenchmarkBoost Price TargetBuy$82.00 ➝ $100.00Low
10/28/2020Cantor FitzgeraldBoost Price TargetOverweight$90.00 ➝ $95.00Low
10/28/2020Piper SandlerBoost Price TargetNeutral$70.00 ➝ $86.00Low
7/29/2020Craig HallumLower Price TargetBuy$102.00 ➝ $85.00Medium
7/29/2020Cantor FitzgeraldBoost Price TargetOverweight$85.00 ➝ $90.00High
7/29/2020Piper SandlerLower Price TargetNeutral$76.00 ➝ $70.00High
7/6/2020StephensInitiated CoverageOverweight$90.00Medium
5/8/2020BenchmarkLower Price TargetBuy$96.00 ➝ $82.00High
5/8/2020Cantor FitzgeraldLower Price TargetOverweight$95.00 ➝ $85.00High
5/8/2020Piper SandlerLower Price TargetNeutral$88.00 ➝ $76.00High
2/7/2020Piper SandlerReiterated RatingHold$88.00Medium
2/7/2020Dougherty & CoBoost Price TargetBuy$92.00 ➝ $100.00High
1/8/2020Wells Fargo & CompanyBoost Price TargetEqual Weight$80.00 ➝ $85.00Low
12/11/2019Cantor FitzgeraldReiterated RatingOverweight$91.00 ➝ $95.00Low
11/21/2019Dougherty & CoBoost Price TargetBuy$90.00 ➝ $92.00Medium
10/25/2019SidotiSet Price TargetHold$82.00N/A
7/26/2019Craig HallumUpgradeHold ➝ Buy$85.00Low
4/26/2019BenchmarkBoost Price TargetBuy$82.00 ➝ $90.00Low
4/26/2019Craig HallumDowngradeBuy ➝ Hold$84.00Low
3/7/2019Dougherty & CoBoost Price TargetBuy$78.00 ➝ $90.00Low
2/8/2019Piper Jaffray CompaniesReiterated RatingNeutral$70.00High
12/7/2018OppenheimerBoost Price TargetOutperform$86.00Low
12/6/2018Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$70.00 ➝ $80.00Low
10/29/2018Wells Fargo & CompanyBoost Price TargetMarket Perform ➝ Market Perform$59.00 ➝ $61.00Medium
10/26/2018OppenheimerBoost Price TargetOutperform ➝ Outperform$71.00 ➝ $73.00N/A
10/26/2018Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$63.00 ➝ $70.00High
10/5/2018BenchmarkBoost Price TargetBuy$66.00 ➝ $79.00Low
9/17/2018Craig HallumBoost Price TargetBuy$65.00 ➝ $80.00Medium
7/27/2018Piper Jaffray CompaniesBoost Price TargetNeutral ➝ Neutral$44.00 ➝ $55.00High
7/27/2018Craig HallumUpgradeHold ➝ Buy$33.00High
7/26/2018Cantor FitzgeraldReiterated RatingBuy$63.00High
6/29/2018BenchmarkInitiated CoverageBuy ➝ Buy$63.00Low
4/3/2018Cantor FitzgeraldReiterated RatingBuy$63.00Medium
2/2/2018Piper Jaffray CompaniesBoost Price TargetNeutral ➝ Neutral$38.00 ➝ $44.00High
2/2/2018Craig HallumDowngradeBuy ➝ HoldHigh
2/1/2018Cantor FitzgeraldReiterated RatingBuy$63.00High
1/29/2018OppenheimerReiterated RatingBuy$55.00Medium
12/13/2017Cantor FitzgeraldReiterated RatingBuy$60.00Medium
12/5/2017Cantor FitzgeraldReiterated RatingBuy$60.00Low
12/5/2017OppenheimerReiterated RatingBuy$55.00Low
10/30/2017Craig HallumReiterated RatingBuy$52.00 ➝ $62.00N/A
10/27/2017Cantor FitzgeraldBoost Price TargetOverweight$58.00N/A
10/19/2017OppenheimerReiterated RatingBuy$55.00N/A
9/5/2017BenchmarkBoost Price TargetBuy ➝ Buy$55.00 ➝ $67.00Medium
7/30/2017Piper Jaffray CompaniesReiterated RatingHold$40.00Medium
7/28/2017Dougherty & CoBoost Price TargetBuy$45.00 ➝ $49.00High
7/28/2017Craig HallumBoost Price TargetBuy$46.00 ➝ $52.00High
7/25/2017Cantor FitzgeraldReiterated RatingBuy$47.00Medium
6/13/2017Cantor FitzgeraldReiterated RatingOverweight$43.00 ➝ $47.00Low
4/26/2017CIBCBoost Price TargetOutperform$43.00 ➝ $53.00Low
4/25/2017OppenheimerReiterated RatingOutperform$43.00 ➝ $53.00High
4/21/2017Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$40.00High
3/6/2017Cantor FitzgeraldBoost Price TargetOverweight$38.00 ➝ $43.00N/A
1/19/2017Dougherty & CoInitiated CoverageBuy$44.00N/A
1/5/2017Cantor FitzgeraldInitiated CoverageOverweight$40.00N/A
12/6/2016BenchmarkBoost Price TargetBuy$39.00 ➝ $55.00N/A
10/27/2016OppenheimerSet Price TargetBuy$46.00N/A
9/13/2016OppenheimerReiterated RatingOutperform$46.00N/A
9/8/2016SidotiDowngradeBuy ➝ Neutral$43.00N/A
7/29/2016(FBRC)Boost Price TargetOutperform$40.00 ➝ $41.00N/A
7/7/2016(FBRC)Boost Price TargetOutperform$35.00 ➝ $40.00N/A
(Data available from 6/22/2016 forward)
Omnicell logo
Omnicell, Inc., together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. In addition, the company provides automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; single dose automation solutions to fill and label for incoming prescriptions; semi-automated filling equipment for the long-term care institutional pharmacy; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.
Read More

Today's Range

Now: $146.96
Low: $143.71
High: $148.19

50 Day Range

MA: $138.54
Low: $129.91
High: $146.96

52 Week Range

Now: $146.96
Low: $62.24
High: $148.19

Volume

265,650 shs

Average Volume

351,558 shs

Market Capitalization

$6.35 billion

P/E Ratio

190.86

Dividend Yield

N/A

Beta

1.06

Frequently Asked Questions

What sell-side analysts currently cover shares of Omnicell?

The following Wall Street sell-side analysts have issued stock ratings on Omnicell in the last year: Benchmark Co., Berenberg Bank, BTIG Research, Cantor Fitzgerald, Craig Hallum, JPMorgan Chase & Co., Piper Sandler, Stephens, TheStreet, and Wells Fargo & Company.
View the latest analyst ratings for OMCL.

What is the current price target for Omnicell?

8 Wall Street analysts have set twelve-month price targets for Omnicell in the last year. Their average twelve-month price target is $129.25, suggesting a possible downside of 12.1%. BTIG Research has the highest price target set, predicting OMCL will reach $165.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $84.00 for Omnicell in the next year.
View the latest price targets for OMCL.

What is the current consensus analyst rating for Omnicell?

Omnicell currently has 3 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OMCL will outperform the market and that investors should add to their positions of Omnicell.
View the latest ratings for OMCL.

What other companies compete with Omnicell?

How do I contact Omnicell's investor relations team?

Omnicell's physical mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company's listed phone number is 650-251-6100 and its investor relations email address is [email protected] The official website for Omnicell is www.omnicell.com.